Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study

Next Previous
Trial Profile

Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flecainide (Primary) ; Propafenone (Primary) ; Sotalol (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms POWDER-AF2

Most Recent Events

  • 01 Nov 2023 Results (n=200) assessing the benefit of continuing previously ineffective class 1C or 3 antiarrhythmic drug therapy (ADT) in the setting of a standardized PVI-only ablation strategy, published in the Circulation: Arrhythmia and Electrophysiology.
  • 08 Jul 2022 Status changed from active, no longer recruiting to completed.
  • 04 Jun 2021 Planned End Date changed from 31 Mar 2021 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top